Healthy Late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization

Early Human Development

Volumn 91, Issue 9, 2015, Pages 541-546

  Helfrich, Alison M ^a,b   Nylund, Cade M ^b   Eberly, Matthew D ^b   Eide, Matilda B ^b   Stagliano, David R ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Bronchiolitis; Late preterm; Lower respiratory tract infection; Palivizumab; Prematurity; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; ASSISTED VENTILATION; CHILDHOOD DISEASE; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; LATE PRETERM INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PREMATURITY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA;

FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT; INFANT, PREMATURE; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 84937946097     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2015.06.009     Document Type: Article

References (30)

1. Black C.P. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 2003 Mar, 48(3):209-231. [discussion 231-3].
2. McLaurin K.K., Hall C.B., Jackson E.A., Owens O.V., Mahadevia P.J. Persistence of morbidity and cost differences between late-preterm and term infants during the first year of life. Pediatrics 2009 Feb, 123(2):653-659.
3. Gunville C.F., Sontag M.K., Stratton K.A., Ranade D.J., Abman S.H., Mourani P.M. Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness. J Pediatr Aug 2010, 157(2). [209-214.e1].
4. Stockman L.J., Curns A.T., Anderson L.J., Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J Jan 2012, 31(1):5-9.
5. Stewart D.L., Romero J.R., Buysman E.K., Fernandes A.W., Mahadevia P.J. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention. Curr Med Res Opin Nov 2009, 25(11):2795-2804.
6. Forbes M.L., Hall C.B., Jackson A., Masaquel A.S., Mahadevia P.J. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life. J Med Econ Mar 2010, 13(1):136-141.
7. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics Sep 1998, 102(3 Pt 1):531-537.
8. Arnold S.R., Wang E.E., Law B.J., Boucher F.D., Stephens D., Robinson J.L., et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J Oct 1999, 18(10):866-869.
9. Purcell K., Fergie J. Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatr Infect Dis J May 2004, 23(5):418-423.
10. Feltes T.F., Cabalka A.K., Meissner H.C., Piazza F.M., Carlin D.A., Top F.H., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr Oct 2003, 143(4):532-540.
11. Wilkesmann A., Ammann R.A., Schildgen O., Eis-Hubinger A.M., Muller A., Seidenberg J., et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J Jun 2007, 26(6):485-491.
12. Couch R.B., Englund J.A., Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med Mar 17 1997, 102(3A):2-9. [discussion 25-6].
13. Resch B., Pasnocht A., Gusenleitner W., Muller W. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect Jun 2005, 50(5):397-403.
14. Stagliano D.R., Nylund C.M., Eide M.B., Eberly M.D. Children with Down syndrome are high-risk for severe respiratory syncytial virus disease. J Pediatr Mar 2015, 166(3). [703-709.e2].
15. Committee on Infectious Diseases From the American Academy of Pediatrics: policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics Dec 2009, 124(6):1694-1701.
16. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics Aug 2014, 134(2):415-420.
17. Martin J.A., Hamilton B.E., Ventura S.J., Osterman M.J., Curtin S.C., Mathews T.J. Births: final data for 2013. Natl Vital Stat Rep Jan 2015, 64(1):1-68.
18. American Academy of Pediatrics/American College of Obstetricians and Gynecologists Guidelines for perinatal care 2002, American Academy of Pediatrics, Elk Grove Village, IL. 5th ed.
19. Engle W.A., Tomashek K.M., Wallman C. Committee on Fetus and Newborn, American Academy of Pediatrics. "Late-preterm" infants: a population at risk. Pediatrics Dec 2007, 120(6):1390-1401.
20. Colin A.A., McEvoy C., Castile R.G. Respiratory morbidity and lung function in preterm infants of 32 to 36weeks' gestational age. Pediatrics Jul 2010, 126(1):115-128.
21. US Department of Defense Demographics 2010: Profile of the military community 2010, 1-185. Office of the Deputy Under Secretary of Defense (Military Community and Family Policy).
22. Barrett J.P., Sevick C.J., Conlin A.M., Gumbs G.R., Lee S., Martin D.P., et al. Validating the use of ICD-9-CM codes to evaluate gestational age and birth weight. J Registry Manag Summer 2012, 39(2):69-75.
23. Borchers A.T., Chang C., Gershwin M.E., Gershwin L.J. Respiratory syncytial virus-a comprehensive review. Clin Rev Allergy Immunol Dec 2013, 45(3):331-379.
24. Ochola R., Sande C., Fegan G., Scott P.D., Medley G.F., Cane P.A., et al. The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One Dec 2 2009, 4(12):e8088.
25. Friedrich L., Pitrez P.M., Stein R.T., Goldani M., Tepper R., Jones M.H. Growth rate of lung function in healthy preterm infants. Am J Respir Crit Care Med Dec 15 2007, 176(12):1269-1273.
26. Manzoni P., Paes B., Resch B., Carbonell-Estrany X., Bont L. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Hum Dev May 2012, 88(Suppl. 2):S34-S41.
27. Maritz G.S., Morley C.J., Harding R. Early developmental origins of impaired lung structure and function. Early Hum Dev Sep 2005, 81(9):763-771.
28. Andabaka T., Nickerson J.W., Rojas-Reyes M.X., Rueda J.D., Bacic Vrca V., Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev Apr 30 2013, 4:CD006602.
29. Olabarrieta I., Gonzalez-Carrasco E., Calvo C., Pozo F., Casas I., Garcia-Garcia M.L. Hospital admission due to respiratory viral infections in moderate preterm, late preterm and term infants during their first year of life. Allergol Immunopathol (Madr) Nov 2014, 8.
30. Hall C.B., Weinberg G.A., Blumkin A.K., Edwards K.M., Staat M.A., Schultz A.F., et al. Respiratory syncytial virus-associated hospitalizations among children less than 24months of age. Pediatrics Aug 2013, 132(2):e341-e348.